ARTL (Artelo Biosciences) Accounts Payable: $1.30 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARTL Artelo Biosciences Inc ARTL
28 GF Score
Price $0.72
! 2 Warning Signs
View Full Analysis

What is Artelo Biosciences Accounts Payable?

Artelo Biosciences ARTL +0.15% 28 Accounts Payable is $1.30 Mil as of Jun. 2026. GuruFocus rates ARTL with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Artelo Biosciences's Accounts Payable for the quarter that ended in Jun. 2026 was $1.30 Mil.

Artelo Biosciences's quarterly Accounts Payable increased from Dec. 2025 ($3.04 Mil) to Mar. 2026 ($4.04 Mil) but then declined from Mar. 2026 ($4.04 Mil) to Jun. 2026 ($1.30 Mil).

Artelo Biosciences's annual Accounts Payable increased from Dec. 2023 ($1.24 Mil) to Dec. 2024 ($1.68 Mil) and increased from Dec. 2024 ($1.68 Mil) to Dec. 2025 ($3.04 Mil).

Artelo Biosciences Accounts Payable Related Terms

Artelo Biosciences Accounts Payable Historical Data

* Premium members only.

The historical data trend for Artelo Biosciences's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artelo Biosciences Accounts Payable Chart

Artelo Biosciences Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 0.91 1.24 1.68 3.04

Artelo Biosciences Quarterly Data
Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.84 3.87 3.04 4.04 1.30
ARTL
28GF Score
Artelo Biosciences Inc ARTL
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artelo Biosciences Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $1.30 Mil mean?
Artelo Biosciences (ARTL) has a Accounts Payable of $1.30 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Artelo Biosciences and its competitors.
Is Artelo Biosciences' Accounts Payable too high?
Artelo Biosciences' current Accounts Payable is $1.30 Mil. Overall, Artelo Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Artelo Biosciences' Accounts Payable compare to ADTX and GOVX?
Artelo Biosciences' Accounts Payable of $1.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Artelo Biosciences and its competitors. Artelo Biosciences's current Accounts Payable is $1.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artelo Biosciences stock overvalued right now?
Artelo Biosciences (ARTL) has a current Accounts Payable of $1.30 Mil. The current Accounts Payable is $1.30 Mil. Artelo Biosciences' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Artelo Biosciences (ARTL), the current Accounts Payable is $1.30 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Artelo Biosciences Business Description

Address 505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
28GF Score

Get the complete analysis for ARTL

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.72
Price